Item 7.01 Regulation FD Disclosure.

Beginning on May 17, 2021, BioVie Inc. (the "Company") plans to make a series of investor presentations (the "Corporate Presentation" and the "R&D Day Presentation") copies of which is attached as Exhibit 99.1 and 99.2, respectively; to this Current Report on Form 8-K and is incorporated herein by reference. The Company also expects to use the Investor Presentation at the BRiley Conference beginning on May 19, 2021 and from time to time thereafter in connection with presentations to potential investors, industry analysts and others. The Investor Presentation is available under the "Events and Presentations" tab in the "Investors" section of the Company's website, located at www.biovie.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Corporate Presentation and the R&D Day Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
 Number    Description
  99.1       Corporate presentation dated May 2021
  99.2       R&D presentation dated May 19, 2021

* Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of

Regulation S-K. The Company will furnish the omitted schedules and exhibits to

the Securities and Exchange Commission upon request.

© Edgar Online, source Glimpses